Real-world comparison of enzalutamide and apalutamide in metastatic hormone-sensitive prostate cancer: a multi-institutional propensity score-matched analysis

Key Points

• The aim is to compare the effects of enzalutamide and apalutamide in a real-world patient cohort.
• Multi-institutional propensity score-matched analysis conducted in a Japanese cohort
• Evaluated PSA responses, progression-free survival, and overall survival
• Assessed treatment discontinuation due to adverse events
• Both enzalutamide and apalutamide showed comparable PSA responses and overall survival
• Apalutamide associated with shorter time to treatment failure and more frequent treatment discontinuation due to adverse events
• Reduced-dose initiation was more common with apalutamide without a disadvantage in treatment progression